glp-1 prescriptions growth slowdown 2024 increase by 364% whilst BMS declines by 42% GLP-1 Agonists Market Report 2025-2033,

Lower doses may work but typically require more time to produce noticeable effects

The front store drives a disproportionate share of Walgreens labor and occupancy operating expenses 61.5% -- versus 38.5% for the pharmacy operation

The most important safety feature is the presence of a plan

[Source: Fierce Pharma ] January 2025 The FDA fast-tracked tirzepatide for cardiovascular risk reduction in obesity patients, following landmark trial results showing significant benefit beyond weight loss

This equates to not being suitable for those with Diabetes, type 1 or 2 whom are on medications or insulin

I wonder if the article was actually about the affect on B12 of liver damaged caused by over drinking